These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33051905)

  • 1. Tumor-Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity.
    Ryu JH; Yoon HY; Sun IC; Kwon IC; Kim K
    Adv Mater; 2020 Dec; 32(51):e2002197. PubMed ID: 33051905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chitosan Nanoparticles for Targeted Cancer Therapy: A Review of Stimuli-Responsive, Passive, and Active Targeting Strategies.
    Al-Shadidi JRMH; Al-Shammari S; Al-Mutairi D; Alkhudhair D; Thu HE; Hussain Z
    Int J Nanomedicine; 2024; 19():8373-8400. PubMed ID: 39161363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DePEGylation strategies to increase cancer nanomedicine efficacy.
    Kong L; Campbell F; Kros A
    Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
    Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-targeting glycol chitosan nanoparticles as a platform delivery carrier in cancer diagnosis and therapy.
    Lee SJ; Min HS; Ku SH; Son S; Kwon IC; Kim SH; Kim K
    Nanomedicine (Lond); 2014 Aug; 9(11):1697-713. PubMed ID: 25321170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
    Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
    AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyaluronic Acid-Bilirubin Nanoparticles as a Tumor Microenvironment Reactive Oxygen Species-Responsive Nanomedicine for Targeted Cancer Therapy.
    Lee S; Lee SA; Shinn J; Lee Y
    Int J Nanomedicine; 2024; 19():4893-4906. PubMed ID: 38828202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved Targeting of Cancers with Nanotherapeutics.
    Foster C; Watson A; Kaplinsky J; Kamaly N
    Methods Mol Biol; 2017; 1530():13-37. PubMed ID: 28150194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-functional chitosan-based nanoparticles for drug delivery: Recent advanced insight into cancer therapy.
    Tian B; Hua S; Liu J
    Carbohydr Polym; 2023 Sep; 315():120972. PubMed ID: 37230614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery.
    Koo H; Min KH; Lee SC; Park JH; Park K; Jeong SY; Choi K; Kwon IC; Kim K
    J Control Release; 2013 Dec; 172(3):823-31. PubMed ID: 24035978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing Stimuli-Responsive Upconversion Nanoparticles that Exploit the Tumor Microenvironment.
    Ovais M; Mukherjee S; Pramanik A; Das D; Mukherjee A; Raza A; Chen C
    Adv Mater; 2020 Jun; 32(22):e2000055. PubMed ID: 32227413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tumor microenvironments on targeted delivery of glycol chitosan nanoparticles.
    Yhee JY; Jeon S; Yoon HY; Shim MK; Ko H; Min J; Na JH; Chang H; Han H; Kim JH; Suh M; Lee H; Park JH; Kim K; Kwon IC
    J Control Release; 2017 Dec; 267():223-231. PubMed ID: 28917532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicines Targeting the Tumor Microenvironment.
    Tong R; Langer R
    Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological rationale for the design of polymeric anti-cancer nanomedicines.
    Zhou Y; Kopeček J
    J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-assembled glycol chitosan nanoparticles for disease-specific theranostics.
    Yhee JY; Son S; Kim SH; Park K; Choi K; Kwon IC
    J Control Release; 2014 Nov; 193():202-13. PubMed ID: 24845129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.
    Chen S; Yang K; Tuguntaev RG; Mozhi A; Zhang J; Wang PC; Liang XJ
    Nanomedicine; 2016 Feb; 12(2):269-86. PubMed ID: 26707818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor targeting strategies for chitosan-based nanoparticles.
    Zhang X; Yang X; Ji J; Liu A; Zhai G
    Colloids Surf B Biointerfaces; 2016 Dec; 148():460-473. PubMed ID: 27665379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.